Ackman Threatens To Sue Allergan Over Salix Deal [LETTER]

0
Ackman Threatens To Sue Allergan Over Salix Deal [LETTER]

Bill Ackman is not happy about talks regarding a potential deal between Salix Pharmaceuticals, Ltd. (SLXP) and Allergen. Ackman wants Allergan to sign a deal with VRX and is demanding that the BOD of Allergen commit to the VRX deal. David Gelles of DealBook reported moments ago that Ackman threatened to sue Allergen over the matter – ValueWalk has obtained the letter, in which Ackman threatened to sue AGN.

Bill Ackman of Pershing Square’s letter to the Board of Directors of Allergan, Inc. (NYSE:AGN).

September 23, 2014

Crypto Hedge Fund Three Arrows Blows Up, Others Could Follow

CryptoA few years ago, crypto hedge funds were all the rage. As cryptocurrencies rose in value, hundreds of hedge funds specializing in digital assets launched to try and capitalize on investor demand. Some of these funds recorded double-digit gains in 2020 and 2021 as cryptocurrencies surged in value. However, this year, cryptocurrencies have been under Read More

Mr. David E. I. Pyott,

Mr. Michael R. Gallagher

Mr. Russ ell T. Ray

Dr. Trevor Mervyn Jones

Mr. Louis J. Lavigne

Dr. Deborah Dunsire

Dr. Peter J. McDonnell

Mr. Timothy D. Proctor

Mr. Henri A. Termeerstev murr

To the Board of Directors of Allergan, Inc. (NYSE:AGN):

We have read published reports t hat you are negotiating a substantial highly leveraged acquisition that would not require shareholder approval i n an attempt to preclude a transaction with Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX). This action would directly contradict your repeated published statements

that: “While Allergan, Inc. (NYSE:AGN) does not believe that Valeant’s offer provides compelling value relative to the alternatives available to the Company, the Allergan Board of Directors fully supports the right of shareholders to vote on the value pro position offered by Valeant at the appropriate time.”

By undertaking an acquisition without a shareholder vote, with the purpose and desired effect of frustrating a Valeant transaction, you are breaching your commitment that shareholders would have a vote on the value proposition offered by Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX). We do not believe you can lawfully undertake such a transaction, particularly given your failure to engage with Valeant.

If you take such action we will immediately bring litigation against you (and any counter-party that aids and abets you) for breach of fiduciary duty.

PERSHING SQUARE CAPITAL MANAGEMENT, L.P.

Sincerely,

William A. Ackman

Chief Executive Officer

Updated on

Sheeraz is our COO (Chief - Operations), his primary duty is curating and editing of ValueWalk. He is main reason behind the rapid growth of the business. Sheeraz previously ran a taxation firm. He is an expert in technology, he has over 5.5 years of design, development and roll-out experience for SEO and SEM. - Email: sraza(at)www.valuewalk.com
Previous article West Coast Warming Due To Natural Factors, Not Global Warming
Next article Alibaba Group Holding Ltd IPO Sends Yahoo! Inc. Stock Tumbling

No posts to display